Loading...
01/11 16:19
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: a 10.6% revenue increase and positive guidance are offset by higher losses, negative cash flow, and asset impairments. Share repurchases and margin improvements are positive, but uncertainties in Medicare funding and unclear management responses introduce risk. The lack of significant new partnerships or guidance changes tempers potential positive sentiment, suggesting a neutral stock price movement.
Revenue $209,000,000 for the quarter, a 10.6% increase compared to $188,900,000 in the second quarter of fiscal year 2024, primarily driven by an increase in member months due to growth in existing California and Colorado centers and the addition of two de novo centers in Florida.
Center Level Contribution Margin $37,100,000 representing a 17.7% margin, a 90 basis point increase compared to 16.8% in the first quarter of fiscal year 2025.
Adjusted EBITDA $5,900,000 for the quarter, compared to $6,900,000 in the second quarter of fiscal year 2024, with an adjusted EBITDA margin of 2.8%.
Census 7,480 participants, reflecting over 10% year-over-year growth compared to the second quarter of fiscal year 2024.
External Provider Costs $107,900,000, an increase of approximately 6.8% compared to the second quarter of fiscal year 2024, primarily driven by an increase in member months, partially offset by a decrease in cost per participant.
Cost of Care (excluding depreciation and amortization) $64,100,000, an increase of 17.9% compared to the second quarter of fiscal year 2024, primarily due to an increase in member months and higher salaries, wages, and benefits.
Net Loss $13,500,000 compared to a net loss of $3,800,000 in the second quarter of fiscal year 2024, impacted by an impairment of right of use asset and construction in progress of approximately $8,500,000.
Cash Flow from Operations Negative cash flow of $6,800,000 for the quarter.
Corporate, General and Administrative Expenses $28,100,000, an increase of 11.3% compared to the second quarter of fiscal year 2024, primarily due to increased employee compensation and benefits.
Sales and Marketing Expenses Approximately $7,700,000, an increase of 31.5% compared to the second quarter of fiscal year 2024, primarily due to increased headcount and marketing to support growth.
Total Debt $78,300,000 on the balance sheet.
Cash and Cash Equivalents $46,100,000, plus $40,800,000 in short-term investments.
Pharmacy Acquisition: Innovage acquired a small pharmacy in Denver to enhance compliance, improve participant outcomes, and reduce costs previously paid to third parties.
PACE Center Growth: Approximately 50 new PACE centers have opened across the country, a 16% increase from the roughly 300 centers operating in January 2022.
Medicaid Rate Increases: Medicaid rate increases in California and Pennsylvania for 2025 reflect cost trends.
Census Growth: Census grew to 7,480 participants, reflecting a 4% quarter-over-quarter increase and over 10% year-over-year growth.
Operational Efficiencies: New President and COO, Michael Scarborough, is driving operational improvements through a technology-first mindset.
Transformation Strategy: The next 18 months will focus on reimagining operations, enhancing payer capabilities, and integrating technology to improve efficiency and participant satisfaction.
Regulatory Compliance Risks: The company is currently undergoing state audit processes in California, which remain open in Sacramento and San Bernardino. This ongoing scrutiny poses a risk to operational stability and compliance.
Enrollment Processing Delays: State-driven enrollment processing delays, particularly in California, are impacting gross and net enrollment figures. These delays can lead to higher allowances against accounts receivable and corresponding write-offs.
Market Competition: The Medicare Advantage environment is experiencing disruptions, which may affect the company's ability to attract and retain participants. Competitors are adjusting their offerings, which could impact Innovage's market position.
Financial Variability: The company has experienced quarter-to-quarter variability in financial results due to one-time adjustments and the inherent seasonality of its business, which may affect investor confidence.
De Novo Center Losses: The company anticipates de novo losses for fiscal year 2025 to be in the range of $18 million to $20 million, which could impact overall profitability.
Impairment of Assets: An impairment of approximately $8.5 million was recorded related to halting development on a previously planned de novo center in Louisville, Kentucky, indicating potential challenges in market entry and asset management.
Economic Factors: The company is closely monitoring economic factors that could affect Medicaid and Medicare funding, particularly in light of new administration policies and potential changes in reimbursement rates.
Clinical Initiatives: The company is seeing positive momentum from its clinical value initiatives, which are expected to reach full impact in the latter half of the fiscal year, potentially leading to additional financial upside.
PACE Expansion: Innovage is actively engaged with policymakers to shape policies that enable the expansion of the PACE model, which has seen a 16% increase in centers over the past three years.
Technology Investments: Investments in technology are being made to improve workflows, enhance participant engagement, and streamline enrollment processes.
Pharmacy Acquisition: The acquisition of a small pharmacy in Denver aims to enhance compliance, improve participant outcomes, and reduce costs by bringing critical capabilities in-house.
Operational Improvements: The new President and COO is focusing on operational rigor and evaluating key areas for improvement through a technology-first mindset.
Fiscal Year 2025 Guidance: The company reaffirms its fiscal year 2025 guidance, projecting total revenue between $815 million and $865 million, adjusted EBITDA between $24 million and $31 million, and ending census between 314,750 participants.
Medicaid Rate Increases: Innovage received mid to high single-digit Medicaid rate increases in California and Pennsylvania effective January 1, 2025.
De Novo Losses: Projected de novo losses for fiscal year 2025 are expected to be in the range of $18 million to $20 million.
Census Growth: The company anticipates continued growth in census, with member months projected to be between 86,000 and 89,000.
Share Repurchase Program: During the quarter, the company repurchased approximately 200,000 shares of its common stock for an aggregate of approximately $1,100,000 under the company's share repurchase plan.
The earnings call presented strong financial results with a 15% revenue increase and a significant improvement in adjusted EBITDA. Despite challenges like higher costs and regulatory risks, the company achieved its first positive net income since 2021. The Q&A highlighted confidence in guidance and effective cost management, though some responses lacked clarity. Overall, the optimistic financial performance and strategic focus on operational efficiency suggest a positive stock price movement in the near term.
Despite strong census growth and improved EBITDA margins, the increase in net loss and higher operational costs, along with uncertainties around B-28 and Medicaid redeterminations, create a mixed outlook. The positive aspects, such as partnerships and automation efforts, are counterbalanced by these challenges, leading to a neutral sentiment.
The earnings call presents a mixed picture: a 10.6% revenue increase and positive guidance are offset by higher losses, negative cash flow, and asset impairments. Share repurchases and margin improvements are positive, but uncertainties in Medicare funding and unclear management responses introduce risk. The lack of significant new partnerships or guidance changes tempers potential positive sentiment, suggesting a neutral stock price movement.
The earnings call highlights strong financial performance with a 12.4% revenue increase and a 500% rise in adjusted EBITDA, which is very positive. The share repurchase program expansion also supports stock price appreciation. However, some concerns exist regarding de novo losses and operational challenges. The Q&A section indicates optimism about enrollment trends and operational efficiencies. Overall, the positive financial results and strategic initiatives outweigh the challenges, leading to a positive sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
